(1) 我有足夠的時間去理解此項檢測的性質以及相關的費用。 我同意並允許安高生命醫學有限公司收集我的樣品和醫療資料去進行表格中所要求的檢測服務，並可以保留匿名的檢測結果作為將來研究用途。我做檢測的決定完全出於自願，沒有接受任何外界臨床人員和其他成員的壓力。
I give my consent to permit OncoSeek Ltd for the collection of my samples and medical information to perform medical testing requested on this form and retain the de-identified results for future research purposes. My decision of testing my clinical materials is truly voluntary and there has not been any external pressure from clinical staff or other members.
(2) 安高生命醫學有限公司的檢測主要是應用在已確診的 癌症病人上作監測病情之用。安高生命醫學提供技術性報告，而其報告不能取代現有的癌症診斷方法。請向醫生徵詢醫學意見。安高生命醫學不會提供任何醫療建議以及參與任何癌症診 斷。檢測的報告不代表安高生命醫學有限公司與醫生/患者建立關係。根據安高生命醫學有限 公司的臨床研究, 截至 2021 年 3 月, 肝癌microRNA指紋測試的敏感度及特異度為 91%。檢測對肝細胞癌症檢測有 9%假陰性和 9%假陽性。
The test provided by OncoSeek Ltd is intended to monitor disease progression in cancer patients. The test is not intended to replace current approaches for cancer diagnosis. Please consult your healthcare providers whenever necessary. OncoSeek Ltd does not offer any medical advice and does not participate in the cancer diagnosis; this document does not establish a relationship with physicians/patients. According to our study involving diagnosed lier cancer patients and healthy individuals, the sensitivity and specificity of the hepatocellular carcinoma (HCC) microRNA-based blood test are 91% (data up to March 2021). This indicates 9% false negative false positive rate for hepatocellular carcinoma liver cancer detection.
(3) 安高生命醫學有限公司承諾將以一切合理有效的措施保護病人提供的資料
OncoSeek Ltd is committed to protect the privacy of the patient information with all reasonably available measures.